Analysis of PIK3CA Mutation Concordance and Frequency in Primary and Different Distant Metastatic Sites in Breast Cancer
Cancer Research and Treatment. 2023;55(1):145-154 
Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis
Breast Cancer Research and Treatment. 2023;201(2):161-169
Initiating breast cancer by PIK3CA mutation
Breast Cancer Research. 2012;14(1):
Low incidence of distant metastases in older women with non-metastatic breast cancer treated with primary endocrine therapy
Breast Cancer Research and Treatment. 2023;
PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
Journal of Modern Oncology. 2021;23(2):269-274
PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer
Breast Diseases: A Year Book Quarterly. 2011;22(4):370-371
1464 POSTER Comparison of HER-2 and Hormone Receptor (HR) Status Between Primary Breast Cancer and Corresponding Distant Metastatic Sites With Double Check Assessment
European Journal of Cancer. 2011;47:S188
PIK3CA Mutation Assessment in HR+/HER2− Metastatic Breast Cancer: Overview for Oncology Clinical Practice
Journal of Molecular Pathology. 2021;2(1):42-54
Primary Tumor Staging and Detection of Common Sites of Distant Metastatic Disease
Cancer Metastasis Through the Lymphovascular System. 2022;275-281
6136 POSTER Relatively High Discordant Rate of KRas Mutation Between Primary and Metastatic Sites, and a Different Pattern of KRas Mutational Status According to Metastatic Sites in Korean Patients With Colorectal Cancer
European Journal of Cancer. 2011;47:S433